Recruiting

Observational Study

Sponsor:

Boston Children's Hospital

Code:

NCT06967727

Conditions

Epilepsy-Dyskinesia

Epilepsy

Dyskinesia

EDS

Epilepsy-Dyskinesia Syndomes

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Registry and Natural History of Epilepsy-Dyskinesia Syndromes is focused on gathering longitudinal clinical data as well as biological samples (blood, urine, and/or skin/tissue) from male and female patients, of all ages, who have a genetic diagnosis of epilepsy-dyskinesia syndromes. Through prospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative's goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.

Conditions

Epilepsy-Dyskinesia

Epilepsy

Dyskinesia

EDS

Epilepsy-Dyskinesia Syndomes

Study ID

NCT06967727

Start date

Jun 1, 2025

Status verified date

Aug, 2025

Completion date

Jul, 2030

Anticipated

Primary completion date

Jun 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Having at least one pathogenic or likely pathogenic variant in one of the genes of interest:

AARS2, ADCY5, ALG13, AP3B2, AP4B1, AP4E1, AP4M1, AP4S1, ARX, ATP1A3, CACNA1A, CACNA1E, CACNA2D2, CDKL5, CSTB, DARS2, DLAT, DLD, DNM1, EARS2, EPG5, EPM2A, FARS2, FOXG1, FRRS1L, GABRA1, GABRA2, GABRB2, GABRB3, GABRG2, GNAO1, GRIA2, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2D, HARS2, HNRNPU, HTT, IQSEC2, IRF2BPL, KCNA2, KCNB1, KCNC1, KCNMA1, KCNQ2, KCNQ3, KCNT1, LARS2, MECP2, MEF2C, MTND5, MTTK, MTTL1, NARS2, NHLRC1, PCDH12, PCDH19, PDE10A, PDE2, PDHA1, PDHB, PDHX, PDK3, PDP1, PIGA, PIGN, PIGP, PIGQ, PIGS, PLCB1, POLG, PRRT2, PURA, RHOBTB2, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SETBP1, SETD5, SLC13A5, SLC1A2, SLC25A22, SLC2A1, SMC1A, SNX14, SPTAN1, ST3GAL3, STXBP1, SYNGAP1, SYNJ1, SZT2, TARS2, TBC1D24, UBA5, UBE3A, VAMP2, VARS2, WARS2, WDR45, WWOX, YIF1B, YWHAG, and other genes associated with epilepsy-dyskinesia syndromes.

Exclusion Criteria:

  • Not having a pathogenic or likely pathogenic variants in the genes of interest

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Creation of Biorepository [ Time Frame: 5 years ]
  • Assess Health-Related Quality of Life [ Time Frame: 5 years ]
  • Understanding of Disease Spectrum [ Time Frame: 5 years ]
  • Investigate the Efficacy of Symptomatic Treatments [ Time Frame: 5 years ]

Central Contacts and Locations

Locations

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

More Information

Sponsor

Boston Children's Hospital

Last update posted

Aug 17, 2025

Last verified

Aug, 2025

Keywords

  • epilepsy
  • Epilepsy-Dyskinesia
  • Epilepsy-Dyskinesia Syndrome
  • Dyskinesia
  • movement disorders
  • epileptic encephalopathy
  • neurogenetics
  • PRRT2
  • ATP1A3
  • GNAO1
  • MECP2
  • CACNA1A
  • CDKL5
  • FOXG1
  • SCN1A
  • SCN8A
  • SLC2A1
  • STXBP1
  • UBA5
  • ADCY5

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Boston Children's Hospital on 2025-08-17.